Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCoyle, D-
dc.contributor.authorLee, KM-
dc.contributor.authorMamdani, M-
dc.contributor.authorSabarre, KA-
dc.contributor.authorTingley, K-
dc.identifier.citationHeadache: The Journal of Head and Face Pain, 55: 236–247, (2015)en_US
dc.description.abstractBACKGROUND: In Ontario, approximately $3.8 billion is spent annually on publicly funded drug programs. The annual growth in Ontario Public Drug Program (OPDP) expenditure has been limited to 1.2% over the course of 3 years. Concurrently, the Ontario Drug Policy Research Network (ODPRN) was appointed to conduct drug class review research relating to formulary modernization within the OPDP. Drug class reviews by ODPRN incorporate a novel methodological technique called reimbursement-based economics, which focuses on reimbursement strategies and may be particularly relevant for policy-makers. OBJECTIVES: To describe the reimbursement-based economics approach. METHODS: Reimbursement-based economics aims to identify the optimal reimbursement strategy for drug classes by incorporating a review of economic literature, comprehensive budget impact analyses, and consideration of cost-effectiveness. This 3-step approach is novel in its focus on the economic impact of alternate reimbursement strategies rather than individual therapies. RESULTS: The methods involved within the reimbursement-based approach are detailed. To facilitate the description, summary methods and findings from a recent application to formulary modernization with respect to the drug class tryptamine-based selective serotonin receptor agonists (triptans) used to treat migraine headaches are presented. CONCLUSIONS: The application of reimbursement-based economics in drug policy reforms allows policy-makers to consider the cost-effectiveness and budget impact of different reimbursement strategies allowing consideration of the trade-off between potential cost savings vs increased access to cost-effective treatments.en_US
dc.description.sponsorshipThis research was supported by the Ontario Drug Policy Research Network. CC is a recipient of a Vanier Canada Graduate Scholarship through CIHR (Funding reference number – CGV 121171) and a trainee on the CIHR Drug Safety and Effectiveness Network Meta-Analysis team grant (Funding reference number – 116573).en_US
dc.subjectDrug reimbursementen_US
dc.titleReimbursement-based economics - What is it and how can we use it to inform drug policy reform?en_US
Appears in Collections:Institute for the Environment

Files in This Item:
File Description SizeFormat 
Fulltext.pdf269.52 kBAdobe PDFView/Open

Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.